CV Sciences (CVSI) Change in Receivables (2013 - 2026)
CV Sciences (CVSI) posted Change in Receivables of -$22000.0 for Q1 2026, down 466.67% sequentially from $6000.0 in Q4 2025, and up 78.0% YoY from -$12359.6 in Q1 2025.
CV Sciences (CVSI) Change in Receivables (2013 - 2026) Analysis & Trends
CV Sciences has reported Change in Receivables for 14 years, with the latest figure at -$22000.0 in Q1 2026.
- Quarterly Change in Receivables rose 78.0% year-over-year to -$22000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46000.0 (up 46.51% YoY) and the FY2025 annual result came in at -$124000.0, down 247.62% from the prior year.
- Change in Receivables retreated to -$22000.0 in Q1 2026 per CVSI's latest filing, from $6000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $130000.0 in Q2 2024 and troughed at -$1.1 million in Q1 2022.
- A 5-year average of -$87000.0 and a median of -$22000.0 in 2026 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2024: Change in Receivables tumbled 724.06% in 2022, then surged 382.61% in 2024.
- Over 5 years, Change in Receivables stood at $107000.0 in 2022, then tumbled by 332.71% to -$249000.0 in 2023, then surged by 141.37% to $103000.0 in 2024, then plunged by 94.17% to $6000.0 in 2025, then plunged by 466.67% to -$22000.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$22000.0, $6000.0, and -$142000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44,000.00 |
| Jun 30, 2026 | -44,000.00 |
| Mar 31, 2026 | -22,000.00 |
| Mar 31, 2026 | -22,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | -142,000.00 |
| Sep 30, 2025 | -142,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Jun 30, 2025 | 112,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Sep 30, 2024 | -219,000.00 |
| Sep 30, 2024 | -219,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |